CDA and chronic myelomonocytic leukemia: Recently, the FDA approved ASTX727 [40], an oral formulation of a fixed-dose combination of DAC and cedazuridin (a cytidine deaminase inhibitor), for the treatment of adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.